![paper配图.jpg paper配图.jpg](\upload\jpg\202305\FB91599BE8304E1B9F07DB5BC82A6B21.jpg)
First disclosure of our CCR8 antagonist IPG7236 and its optimization story in Journal of Medicinal Chemistry. The compound exhibited excellent PK profile in human as well as promising anti-tumor activity in Phase I and will be advanced into Phase II stage soon.